Found this little piece;
On September 10, 1998 the FDA moved against Steris Laboratories, Inc. (a division of Schein Pharmaceutical, Inc.), seizing large stocks of their drugs and ordering a halt in further production of all products at that facility; Steris, located in Phoenix, Arizona, laid off about 350 workers. The FDA has not said that any of the drugs are bad, but that the company had not followed required procedures for documenting quality assurance.
Steris had been manufacturing all the generic testosterone cypionate and enanthate sold in the U.S., even that which is sold by other companies.
On October 16, 1998, a "Consent Decree of Condemnation and Permanent Injunction" between the FDA and Steris allowed the company to resume distribution of some but not all of its products. The consent decree (which is public information) includes an "Exhibit C" of drugs which the FDA has determined are medically necessary. Steris will re-test the seized stocks of these drugs, and return them to the market if possible; also, it will resume manufacturing, when permitted, for these products. However, Exhibit C does not include any form of testosterone, apparently because the FDA believed that enough other companies were marketing equivalents of the drug; the FDA has approved about three dozen testosterone preparations of about a dozen different companies, but at this time does not know how many are currently on the market. Exhibit C also includes chorionic gonadotropin 5,000 U/vial and 10,000 U/vial (sometimes used to help restart endogenous testosterone production after discontinuation of testosterone therapy) and nandrolone decanoate 100 mg/mL and 200 mg/mL--suggesting that if any shortages of these drugs develop, they should be temporary.
Steris did list testosterone cypionate and enanthate 200mg/mL in Exhibit A (drugs it wants to resume manufacturing when possible). It lists a lower concentration of both testosterone cypionate and enanthate (100mg/mL)--and also nandrolone decanoate 50mg/mLExhibit B (products it may withdraw from the market).
